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Abstract  45 
Context: The association between monogenic mutations and 46,XX testicular/ovotesticular 46 
disorders of sex development (DSD) remains rather speculative. Although mutations in NR5A1 47 
are known to cause 46,XY gonadal dysgenesis and 46,XX ovarian insufficiency, such mutations 48 
have not been implicated in the testicular development of 46,XX gonads. 49 
Case Description: Patients 1 and 2 were unrelated 46,XX DSD patients who manifested genital 50 
abnormalities at birth. Clinical examinations confirmed the presence of ovotesticular and/or 51 
testicular tissues in the gonads and the absence of uterus and vagina. Molecular analysis of 28 52 
genes involved in gonadal development identified a heterozygous p.R92W mutation of NR5A1 53 
in both patients. This mutation was absent from the clinically normal mothers of patients 1 and 54 
2 and has not been detected in the general population. In silico analysis suggested that p.R92W 55 
is probably pathogenic and likely causes conformational changes at the DNA-binding site. In 56 
vitro assays demonstrated that the mutant protein is resistant to the NR0B1 (nuclear receptor 57 
subfamily 0 group B member 1)-induced suppression on SOX9 TESCO (testis enhancer 58 
sequence core element) activity. While patient 1 carried additional rare polymorphisms in 59 
FOXL2 and WWOX, patient 2 had no other mutations in tested genes. 60 
Conclusions: This study provides the first indication that specific mutations in NR5A1 may 61 
underlie testicular development in 46,XX individuals.  62 
  63 
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46,XX testicular/ovotesticular disorders of sex development (DSD) are rare conditions in which 64 
the developmental process of 46,XX gonads is switched toward testicular formation. 46,XX 65 
testicular DSD usually results from translocations of SRY-containing DNA fragments from Y 66 
chromosomes to X chromosomes (1), while a small percentage of cases is attributed to 67 
chromosomal rearrangements that affect cis-regulatory regions of SOX9 or SOX3 (2). Likewise, 68 
46,XX ovotesticular DSD frequently arises from chromosomal mosaicism or chimerism (3). To 69 
date, monogenic mutations have not been associated with 46,XX testicular/ovotesticular DSD, 70 
except for those in RSPO1 and WNT4, which were identified in a few patients with syndromic 71 
DSD. 72 
Nuclear receptor subfamily 5 group A member 1 (NR5A1, also known as SF1/Ad4BP) 73 
is a transcription factor that regulates gonadal and adrenal development. In mice and possibly in 74 
humans as well, NR5A1 and SRY-box-9 (SOX9) synergistically activate the testis enhancer 75 
sequence core element (TESCO) of Sox9/SOX9 (4). The cooperative transactivation of TESCO 76 
by NR5A1 and SOX9 is antagonized by the nuclear receptor subfamily 0 group B member 1 77 
(NR0B1, also known as DAX1) (5). More than 40 loss-of-function mutations of NR5A1 have 78 
been identified in patients with gonadal dysgenesis and/or adrenal insufficiency (6). NR5A1 79 
abnormality represents one of the major causes of gonadal dysgenesis in genetic males and 80 
accounts for a small fraction of primary ovarian insufficiency in genetic females (6). 81 
Nevertheless, NR5A1 mutations have not been implicated in 46,XX testicular/ovotesticular DSD. 82 
Here, we identified an NR5A1 missense mutation in two unrelated 46,XX individuals with 83 
testicular tissues.  84 
 85 
Subjects and Methods 86 
Case reports 87 
Detailed clinical information of patients 1 and 2 is shown in Table 1 and in the Supplemental 88 
Information. These patients are unrelated Japanese individuals with a 46,XX karyotype. 89 
Patient 1 was raised as a female. At birth, this patient manifested ambiguous external 90 
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genitalia of Prader stage 3–4. Laparoscopy and cystoscopy confirmed the absence of vagina and 91 
uterus. The patient’s blood testosterone level was within the reference range of age-matched 92 
males, while gonadotropin levels were elevated. At 1 year of age, she underwent gonadectomy. 93 
The right and left gonads were found to be immature testis-like tissues and SOX9- and 94 
Forkhead box L2 (FOXL2)-positive ovotestis, respectively.  95 
Patient 2 was raised as a male. At birth, he manifested male-type external genitalia 96 
with hypospadias and bifid scrotum. Gonadal biopsy and laparoscopy at 6 months of age 97 
confirmed the presence of testicular tissues and spermatic cord. Magnetic resonance imaging 98 
indicated the absence of vagina and uterus. His gonadotropin and testosterone levels were 99 
almost comparable to those of unaffected boys. At 9 years and 7 months of age, the patient had 100 
descended testes of 1 mL in volume.  101 
 102 
Molecular analyses 103 
This study was approved by the Institutional Review Board Committee and performed after 104 
obtaining informed consent. Detailed methods are described in the Supplemental Information.  105 
Genomic DNA samples were obtained from patients 1 and 2. Twenty-eight genes 106 
known or predicted to regulate gonadal development were analyzed by next-generation or 107 
Sanger sequencing. We also analyzed copy-number alterations in the genome.  108 
The population frequency of identified substitutions was analyzed using the Exome 109 
Aggregation Consortium (ExAC) Browser, dbSNP, and the Human Genetic Variation Browser 110 
(HGVB). The functional consequences of these mutations were predicted by Polyphen-2 and 111 
MutationTaster, and the three-dimensional structure of mutated NR5A1 was predicted by 112 
PyMOL. When possible, DNA samples of the parents were also analyzed. 113 
 114 
In vitro functional assays 115 
Detailed methods are available in Supplemental Information. We performed luciferase reporter 116 
assays for wildtype NR5A1 and p.R92W. Briefly, Chinese hamster ovary-K1 cells were 117 
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transiently transfected with expression vectors for NR5A1, SOX9, and NR0B1, a reporter vector 118 
containing SOX9 TESCO, and an internal control vector. Relative luciferase activity was 119 




Molecular analyses  124 
The same heterozygous substitution (c.274C>T, p.R92W) in the A-box motif of the NR5A1 125 
DNA-binding domain was detected in patients 1 and 2 (Fig. 1A and B). This substitution was 126 
not found in databases. This substitution was scored “probably damaging” and “disease causing” 127 
by Polyphen-2 and MutationTaster, respectively. Protein modeling predicted that the mutation 128 
induces conformational changes at the DNA-binding site (Fig. 1C). 129 
Patient 1 carried additional substitutions in FOXL2 (c.1045C>G, p.R349G) and 130 
WWOX (c.550C>T, p.L184F), the allele frequencies of which in the ExAC Browser are 131 
32/111,232 and 6/120,756, respectively (Fig. S1). Both substitutions were scored “probably 132 
damaging” and “disease causing”. Patient 2 had no additional mutations in tested genes. 133 
Copy-number alterations were not detected.  134 
In patient 1, the substitutions in NR5A1 and FOXL2 were inherited from the father, 135 
while the WWOX substitution was transmitted from the mother. In patient 2, the NR5A1 136 
substitution was absent from the mother, indicating paternal or de novo origin.  137 
 138 
In vitro functional assays 139 
Both wildtype NR5A1 and the p.R92W mutant activated SOX9 TESCO in cooperation with 140 
SOX9. While NR0B1 repressed the TESCO activation by wildtype NR5A1 in a dose dependent 141 





We detected identical NR5A1 mutations in two unrelated 46,XX individuals with testicular 145 
tissues. The p.R92W mutation affected the functionally important A-box motif of the 146 
DNA-binding domain (7), and has not been identified in the general population. In silico 147 
analysis suggested that p.R92W is “probably damaging” and causes protein conformational 148 
changes. These data indicate that p.R92W is a pathogenic mutation, rather than a benign 149 
polymorphism. Testicular formation in patients 1 and 2 can be explained by assuming that 150 
p.R92W is a gain-of-function mutation that triggers SOX9 overexpression, which is known to 151 
induce the testicular development of immature 46,XX gonads (2). Indeed, in vitro assays 152 
demonstrated that p.R92W is resistant to the NR0B1-induced suppression on SOX9 TESCO 153 
activity. The absence of p.R92W in the patients’ mothers is consistent with the possible 154 
association between this mutation and 46,XX DSD. It is noteworthy that a homozygous 155 
mutation in the same codon, p.R92Q, has been identified in an individual with 46,XY gonadal 156 
dysgenesis and adrenal insufficiency (8), suggesting the functional importance of the arginine 157 
residue at the 92nd position. Differences in the clinical manifestation of p.R92Q and p.R92W 158 
possibly reflect differences in the transactivating activity of these mutants. Indeed, in silico 159 
analysis predicted a structural difference between the mutants (Fig. 1C). Nevertheless, we 160 
cannot exclude the possibility that DSD in our patients developed independently of p.R92W. 161 
Further studies are necessary to clarify the phenotypic consequences of this mutation. 162 
Notably, patient 1 carried additional rare “probably damaging” polymorphisms in 163 
FOXL2 and WWOX. While maternal inheritance of the WWOX polymorphism argues against its 164 
association to 46,XX DSD, the paternally transmitted FOXL2 substitution may have affected 165 
gonadal development. Indeed, FOXL2 is known to interact with NR5A1 (9), and multiple 166 
mutations in FOXL2 have been reported to increase the risk of 46,XX testicular DSD (10). 167 
However, the clinical significance of FOXL2 substitutions seems limited, if any, because 168 
nucleotide changes in the FOXL2 coding region were not found in patient 2, who had a more 169 
severe phenotype than patient 1.  170 
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In summary, this study provides the first indication that specific mutations in NR5A1 171 
may underlie testicular development in 46,XX individuals. This notion needs to be validated in 172 
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Figure legends 213 
Fig. 1. 214 
(A)  The NR5A1 mutation identified in patients 1 and 2. The mutated nucleotide is indicated by 215 
an arrow. This mutation was scored “probably damaging” by Polyphen-2. 216 
(B)  Position of p.R92W. Black and white boxes indicate the coding and non-coding exons of 217 
NR5A1, respectively. This mutation affected the A-box motif (blue box) in the 218 
DNA-binding domain (DBD). HD, hinge domain; LBD, ligand binding domain. 219 
(C) Three-dimensional protein modeling of p.R92W and a known R92Q mutation. NR5A1 and 220 
target DNA are illustrated in pink and blue, respectively. Amino acids at the 92nd codon are 221 
highlighted in red. The p.R92W and p.R92Q mutations probably induce conformational 222 
changes at the DNA-binding site. 223 
(D)  Representative results of luciferase assays using the SOX9 TESCO reporter. Expression 224 
vectors for NR5A1 and SOX9 were transfected into CHO-K1 cells, along with the reporter 225 
vecotor and various doses of NR0B1 expression vector (6.25, 25, 100, 400 ng/well). Results 226 
are expressed as mean ± standard deviation. WT, wildtype NR5A1; MUT, the p.R92W 227 
mutant.  228 
Table 1. Clinical features of patients 1 and 2.        
   Patient 1  Patient 2 
Physical findings at birth         
 External genitalia   ambiguous external genitalia (Prader stage 3-4)  male-type genitalia with hypospadias and bifid scrotum 
 Gonad   not palpable  palpable 
 Histology  testis-like (right), ovotestis (left)  testis 
 Uterus  absent  absent 
Hormonal findings         
 Age at exama days 6 and 13b 1 month  1-5 monthsc 14.8 years 
   basal stimulated basal stimulated  basal stimulated basal 
 LH (mIU/mL)d  9.1 [0.3-1.9 (M), 
0.2-0.7 (F)] 
… … …  0.5 
 [0.1-0.4 (M, F)] 
6.0 [0.4-6.0 (M), 
1.6-4.8 (F)] 
14.0 [0.5-3.1 (M), 
1.3-33.4 (F)] 
 FSH (mIU/mL)d  13.6 [0.8-3.0 (M), 
1.8-8.6 (F)] 
… … …  2.7 [0.6-3.0 (M), 
2.1-6.1 (F)] 
9.4 [6.3-15.6 (M), 
14.5-21.9 (F) 




… … 164 [115-404 
(M), 0-15 (F)] 
566 
[>200 (M)] 
124 [115-404 (M), 
0-15 (F)] 
424 
 [>200 (M)] 
140 [119-349 (M), 
21-67 (F)]  
 AMH (ng/mL)  12.6 [55.6 ± 21.3 
(M), 1.0 ± 0.9 (F)] 
… … …  … … … 
 E2 (pg/mL)f  21 [96 ± 44 (M), 31 
± 32 (F)] 
… … …  10 [46 ± 46 (M), 33 ± 
37 (F)] 
10 [No reference 
data] 
… 
 ACTH (pg/mL)  47 [24 ± 11 (M), 26 
± 12 (F)] 
… … …  … … 21 [23 ± 6 (M), 22 ± 
17 (F)] 
 Cortisol (µg/dL)g  13.4 [12.4 ± 5.3 
(M), 12.8 ± 7.1 (F)] 
46.7 [38.2 ± 4.4 (M), 
10.0 ± 8.1 (F)] 
… …  17.2 [12.4 ± 5.3 (M), 
12.8 ± 7.1 (F)] 
29.3 [38.2 ± 4.4 (M), 
40.0 ± 8.1 (F)] 
7.7 [9.5 ± 2.9 (M), 
10.1 ± 2.8 (F)] 
 17-OHP 
(ng/mL)g 
 … … … …  1.7 
[<20.0 (M, F)] 
3.9 
[<16.6 (M, F)] 
… 
AMH, anti-Müllerian hormone； E2, estradiol; 17-OHP, 17-hydroxyprogesterone.          
Conversion factors to the SI unit: LH, 1.0 (IU/L); FSH, 1.0 (IU/L); testosterone, 0.0347 (nmol/L); AMH, 7.14 (pmol/L); E2, 3.671 (pmol/L); ACTH, 0.22 (pmol/L); cortisol, 27.59 
(nmol/L) and 17-OHP, 3.03 (nmol/L). 
a Reference ranges for age-matched male (M) and female (F) children are shown in brackets.   
b LH, FSH, AMH and E2 were measured at day 6, while ACTH and cortisol were measured at day 13. 
c LH and FSH were measured at 5 months of age, testosterone and E2 were measured at 2 months of age, and cortisol and 17-OHP were measured at 1 month of age. 
d Gonadotropin releasing hormone stimulation test (100 µg/m2, max. 100 µg bolus i.v.; blood sampling at 0, 30, 60, 90, and 120 minutes). 
e Human chorionic gonadotropin stimulation test (750 U, i.m. for 3 consecutive days; blood sampling on days 1 and 4). 
f Human menopausal gonadotropin stimulation test (100 U, i.m. for 3 consecutive days; blood sampling on days 0 and 4). 
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SUPPORTING INFORMATION 1 
 2 
Subjects and Methods 3 
Subjects 4 
Patients 1 and 2 were unrelated patients identified by genital abnormalities at birth. These 5 
patients manifested no additional clinical features. Patient 1 was conceived by in vitro 6 
fertilization. Both patients were born at 41 weeks gestation as the sole child of 7 
non-consanguineous Japanese parents, and had no family history of disorders of sex 8 
development (DSD). G-banding analysis confirmed a 46,XX karyotype. PCR for SRY 9 
yielded no amplification products.  10 
 11 
Ethical approval 12 
This study was approved by the Institutional Review Board Committee at the National 13 
Center for Child Health and Development and performed after obtaining written informed 14 
consent from the participants or their parents. 15 
 16 
Sequence analysis 17 
Genomic DNA samples were obtained from patients 1 and 2, as well as from the parents of 18 
patient 1 and the mother of patient 2. Exome sequencing was performed using the All Exome 19 
v5 Kit (Agilent Technologies, Palo Alto, CA, USA) and the HiSeq 1500 sequencer (Illumina, 20 
San Diego, CA, USA). Sequencing data were analyzed by BWA 0. 6. 2 21 
(http://bio-bwa.souceforge.net/) and SAMtools 0.1.18 software 22 
(http://samtools.soursefrge.net/). In this study, we analyzed protein-altering mutations and 23 
splice-site variations in genes that have previously been associated with human sex 24 
development [Bashamboo and McElreavey, 2013; Ono and Harley, 2013; Eggers et al., 25 
2014; Baxter et al., 2015].  26 
Nucleotide alterations identified in patients 1 and 2 were analyzed in silico. We 27 
2 
 
examined the population frequency of the substitutions in the Exome Aggregation 28 
Consortium (ExAC) Browser (http://exac.broadinstitute.org/), dbSNP 29 
(http://www.ncbi.nlm.nih.gov/snp/), the 1000 Genomes Browser 30 
(http://ncbi.nlm.nih.gov/variation/tools/1000genomes/), and Human Genetic Variation 31 
Browser (HGVB; http://www.genome.med.kyoto-u.ac.jp/SnpDB). DNA samples obtained 32 
from eight healthy Japanese females were used as control. Nucleotide substitutions whose 33 
frequency in the general population is more than 1.0% were excluded as polymorphisms. In 34 
addition, mutations shared by our control samples or by the mothers of patients 1 or 2 were 35 
considered as non-pathogenic. The functional consequences of the substitutions were 36 
predicted by Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/), MutationTaster 37 
(http://www.mutationtaster.org/), and SIFT (http://sift.jcvi.org/), by using the default 38 
parameters. Three-dimensional structures of mutants were predicted by PyMOL 39 
(http://www.pymol.org). Putative pathogenic mutations were confirmed by Sanger 40 
sequencing. Primer sequences are available upon request.  41 
To assess the pathogenicity of an NR5A1 mutation identified in patients 1 and 2, we 42 
performed sequence analysis of 200 healthy Japanese controls (100 males and 100 females). 43 
The samples were obtained from the Human Science Research Resources Bank (Tokyo, 44 
Japan; present distributer, National Institute of Biomedical Innovation, Osaka, Japan). 45 
Furthermore, to examine whether the NR5A1 mutations in patients 1 and 2 share a common 46 
genetic origin, we genotyped several single nucleotide polymorphisms in the NR5A1 locus in 47 
the patients and their family members. 48 
 49 
Submission of mutation data to a database 50 
An NR5A1 substitution identified in this study was submitted to the DNA Data Bank of 51 
Japan (http://www.ddbj.nig.ac.jp/index-j.html; accession number, LC037393). 52 
 53 
Copy-number analysis 54 
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Copy-number changes in the genome of patients 1 and 2 were analyzed by array-based 55 
comparative genomic hybridization using a catalog human array (4 × 180 k format; Agilent 56 
Technologies). We referred to the Database of Genomic Variant 57 
(http://dgv.tcag.ca/dgv/app/home) to exclude benign copy-number polymorphisms.   58 
 59 
Plasmids 60 
Expression vectors for wildtype human NR5A1 and FOXL2 were purchased from Kazusa 61 
DNA Research Institute (Kisarazu, Chiba, Japan). An expression vector for the mutant 62 
NR5A1 and FOXL2 were generated by mutagenesis using the PrimeSTAR Mutagenesis 63 
Basal Kit (Takara Bio, Otsu, Shiga, Japan). An expression vector for NR0B1 and a reporter 64 
vector containing the SOX9 testis enhancer sequence core element (TESCO) were generated 65 
in our previous studies [Okuhara et al., 2008; Sekido and Lovell-Badge, 2008]. An 66 
expression vector for human SOX9 was purchased from OriGene Technologies (MD, USA). 67 
The pRL-null vector (Life Technologies, CA, USA) was used as an internal control for 68 
transfection. 69 
 70 
Luciferase assays 71 
Transactivation activity of wildtype and mutant NR5A1 on SOX9 TESCO was determined 72 
by luciferase reporter assays. Chinese hamster ovary (CHO)-K1 cells and murine Leydig 73 
tumor cells (MLTC1) (ATCC, VA, USA) were seeded in 12-well plates (1.0 × 10
5
 cells/well) 74 
and transiently transfected with 100 ng NR5A1 expression vector, 100 ng SOX9 expression 75 
vector, 500 ng SOX9 TESCO reporter vector, and 100 ng pRL-null control vector, along with 76 
increasing doses of the NR0B1 expression vector (6.25, 25, 100, and 400 ng/well). 77 
Lipofectamine 3000 (Life Technologies) was used for transfection. Relative luciferase 78 
activity was measured 48 hours after transfection, using the Dual Luciferase Reporter Assay 79 
System (Promega, MD, USA). Luciferase activity was measured in triplicate in a single 80 
assay and all assays were repeated three times. Results are expressed as the mean ± standard 81 
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deviation, and statistical significance was determined by t-test. P-values less than 0.05 were 82 
considered significant.  83 
We also analyzed the effects of wildtype FOXL2 and the p.Arg349Gly mutant on 84 
NR5A1- and SOX9-induced SOX9 TESCO activity. In this experiment, CHO cells were 85 
transfected with expression vector for FOXL2 (100 ng/well), along with NR5A1 expression 86 
vector (100 ng/well), SOX9 expression vector (100 ng/well), SOX9 TESCO reporter vector 87 
(500 ng/well), and pRL-null control vector (100 ng/well). Relative luciferase activity was 88 
measured as described above. 89 
 90 
 91 
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Supp. Table S1. In silico functional prediction of NR5A1, FOXL2 and POR substitutions 
 







    Score Prediction  Score Prediction  Score Prediction 






 0.00 damaging 






 0.02 damaging 






 0.00 damaging 
 
In silico analyses were performed by using the default parameters.  
a
MutationTaster (http://www.mutationtaster.org/). Current version: MutationTaster2, GRCh37/Ensembl 
69. 
b
Polyphen-2 (http://genetics.bwh.harvard.edu/pph2), Current version: 2.2.2, GRCh37. Scores between 
0.909 and 1, between 0.447 and 0.908 and below 0.446 denote probably damaging, possibly damaging 
and benign, respectively. 
c
SIFT (http://sift.jcvi.org/www/SIFT_chr_coords_submit.html). Current version: Aug. 2011; 















  Patient 2 
Mother of 
patient 2 
chr9:127244955 rs915034 UTR 
 
A/A A/A N.A. 
 
G/A A/A 
chr9:127245412 rs7037254 intronic 
 
C/C C/C C/T 
 
C/C C/C 
chr9:127253308 N.D. intronic 
 
A/A A/A A/A 
 
C/A A/A 
chr9:127255448 rs2297605 intronic 
 
G/A G/A G/A 
 
A/A A/A 
chr9:127255611 rs76274669 intronic 
 
G/C C/G G/G 
 
G/G G/G 
chr9:127262802 rs1110061 exonic 
 







A/G G/G A/G 
 
A/G G/G 
chr9:127263084 rs1889311 intronic 
 
G/G G/G G/G 
 
G/G G/G 
chr9:127265286 rs115601896 intronic 
 
C/C C/C C/C 
 
C/C C/C 
chr9:127265775 rs76584717 intronic   G/A A/G G/G   G/G G/G 
 
N.A., not analyzed; N.D., no data; UTR, untranslated region.     
a
 Physical position referred to Human Genome (GRCh37/hg19). 
b 
p.Arg92Trp  
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